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http://dx.doi.org/1of patients inChina implantedwith theResolute zotarolimus-eluting stent (R-ZES). R-ZESwas
commercially available before the enrollment began. All patients suitable for R-ZES implan-
tation according to applicable guidelines were candidates for enrollment at 30 centers and were
treated per standard hospital practice. Dual antiplatelet therapy (DAPT) was prescribed for a
minimum of 6 months per current European Society of Cardiology guidelines and the device
instructions for use.Therewere 1,800patients enrolledwith ameanage of 61.3– 10.9years, 76%
of patients weremen, and 61%had complex disease.DAPTusewas 94%at 1 year. Target lesion
failure (cardiac death, target vessel myocardial infarction, or clinically driven target lesion
revascularization) at 1 yearwas3.5%(95%conﬁdence interval 2.7%to 4.5%).The rate of cardiac
death was 0.6%, target vessel myocardial infarction 2.3%, and clinically driven target lesion
revascularization 0.9%. The 1-year rate of deﬁnite or probable stent thrombosis was 0.5% (8 of
1,750); 0.4% (7 of 1,750) occurred early (0 to 30 days) and 1 event occurred late (1 to 12months).
One stent thrombosis occurred in a patient who had an interruption of DAPT within the ﬁrst
month; all other stent thromboses occurred while on DAPT. Outcomes did not differ signiﬁ-
cantly between monitored and unmonitored patients (difference in target lesion failure, p [
0.264). In conclusion, the RESOLUTE China Registry conﬁrms the safety and effectiveness of
R-ZES in a large real-world Chinese population.  2014 The Authors. Published by Elsevier
Inc. (Am J Cardiol 2014;113:613e620)Open access under CC BY-NC-ND license.From 1990 to 2010, coronary heart disease moved from the
seventh to second leading cause of death in China.1 The
emerging challenge of treating cardiovascular disease inChina
has led to an increased interest in the assessment of outcomes in
the Chinese population after drug-eluting stent (DES) im-
plantation in this population. TheResolute zotarolimus-eluting
stent (R-ZES;Medtronic Inc., SantaRosa, California) has been
shown to be safe and effective among all-comers populations
in a European randomized study2,3 and an international reg-
istry that did not include sites in China.4 The RESOLUTE
China Registry, the largest R-ZES study in the Chinese pop-
ulation, was designed to characterize real-world clinical out-
comes of R-ZES in an all-comers population of Chinese
patients requiring stent implantation. The 1-year outcomes of
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The RESOLUTE China Registry was a closed-cohort
observational study that prospectively enrolled patients from
30 sites. Patients were enrolled from December 2010 to
March 2012. Patient follow-up was planned at 30 days,
6 months, and annually through 5 years. The study con-
formed to the Declaration of Helsinki, the protocol was
approved by independent ethics committees for all sites, and
all patients provided written informed consent before
enrollment. The RESOLUTE China Registry was registered
in ClinicalTrials.gov (NCT01243749). The study design
and oversight was directed by a steering committee of study
investigators and a representative from the sponsor.
All patients who were aged 18 years and eligible for
elective implantation of an R-ZES in 1 target lesions were
candidates for enrollment. Patients were excluded if they
had a known intolerance to materials or drugs used in the
study, were pregnant or lactating, were highly unlikely to
adhere to follow-up requirements, had a planned surgery
within 6 months of the index procedure that required
interruption of dual antiplatelet therapy (DAPT), or had
previously enrolled in the RESOLUTE China Registry.
Stent implantation was done according to routine hospital
practice, applicable guidelines, and the R-ZES instructions
for use. Investigators were advised to attempt treatment of
all lesions with R-ZES, but implantation of other stents was
permitted. If delivery failure occurred or there were insuf-
ﬁcient R-ZES available, any DES or bare-metal stent could
be implanted. The protocol recommended DAPT using
aspirin and clopidogrel 75 mg each for 3 days before pro-
cedure or a periprocedural loading dose of aspirin 250 to
500 mg and clopidogrel 300 to 600 mg. The protocol furtherwww.ajconline.org BY-NC-ND license.
Table 1
Baseline demographics and clinical characteristics
Characteristic All Patients (n ¼ 1,800) Monitored (n ¼ 898) Unmonitored (n ¼ 902) p Value*
Age (yrs) 61.3  10.9 61.1  10.9 61.5  10.8 0.458
Men 1,361 (76) 672 (75) 689 (76) 0.476
Current smoker 644 (36) 318 (35) 326 (36) 0.768
Diabetes mellitus 528 (29) 265 (30) 263 (29) 0.877
Insulin dependent 19 (1) 4 (<1) 15 (2) 0.019
Hyperlipidemia 735 (41) 377 (42) 358 (40) 0.338
Hypertension 1,148 (64) 579 (64) 569 (63) 0.556
Previous myocardial infarction 642/1,788 (36) 323/891 (36) 319/897 (36) 0.768
Revascularization for angina or myocardial infarction 0.607
Silent angina 45/1,783 (3) 24/886 (3) 21/897 (2)
Stable angina 133/1,783 (8) 59/886 (7) 74/897 (8)
Unstable angina 1,045/1,783 (58) 524/886 (59) 521/897 (58)
Acute myocardial infarction 560/1,783 (31) 279/886 (32) 281/897 (31)
Serum creatinine (mmol/L) 80.43  31.80 78.74  27.60 82.10  35.41 0.029
Complex patients† 1,102 (61) 537 (60) 565 (63) 0.227
Data are expressed as patients (%) or mean  SD.
* Comparing monitored and unmonitored.
† Complex patients had 1,550 lesions (67%). Refer to the Methods section for the deﬁnition of complex patient status.
614 The American Journal of Cardiology (www.ajconline.org)recommended aspirin 75 mg indeﬁnitely and clopidogrel for
at least 6 months (R-ZES instructions for use and European
guidelines)5 and up to 12 months (American guidelines).6
DAPT use could be continued beyond 12 months by the
physician’s decision.
Site monitoring (R&G PharmaStudies Co Ltd, Shanghai,
China) was prespeciﬁed to be conducted at all sites to verify
100% of informed consent forms and source data from 50%
of patients. Additional monitoring was conducted based on
clinical events committeeeadjudicated events. Data man-
agement and statistical analysis were undertaken by the
sponsor.
Clinical outcomes studied in this registry included target
lesion failure (TLF; deﬁned as cardiac death, target vessel
myocardial infarction [Q wave and noneQ wave], or clin-
ically driven target lesion revascularization) and Academic
Research Consortium7 deﬁnite or probable stent thrombosis.
Other outcomes analyzed included target vessel failure
(cardiac death, target vessel myocardial infarction, or clini-
cally driven target vessel revascularization), major adverse
cardiac events (MACEs; death, myocardial infarction,
emergent coronary artery bypass graft, or clinically driven
target lesion revascularization), a composite outcome (death,
myocardial infarction, or any revascularization), signiﬁcant
bleeding complications, and the components of composite
outcomes. Deaths were considered cardiac unless an un-
equivocal noncardiac cause could be established. Revascu-
larization could have been by percutaneous or surgical
methods. Target vessel myocardial infarction and myocar-
dial infarction were adjudicated according to the extended
historical deﬁnition.8
A bleeding complication was deﬁned as a procedure-
related hemorrhagic event that required a transfusion or
surgical repair (including hematoma requiring treatment of
retroperitoneal bleeding). A signiﬁcant bleeding complica-
tion was deﬁned as intracranial bleeding or bleeding that led
to DAPT interruption, required transfusion, or resulted in
substantial hemodynamic compromise requiring treatment.Effectiveness was measured as attainment of <50% re-
sidual stenosis at the target lesion using any percutaneous
method (lesion success), using only the assigned device
(device success), or resulting in no in-hospital MACE
(procedure success).
Complex patient status was deﬁned as having 1 of the
following characteristics: serum creatinine level140mmol/L,
left ventricular ejection fraction <30%, acute myocardial
infarction (within 72 hours), >1 lesion per vessel, 2 vessels
stented, lesions of>27 mm, bifurcation, bypass graft, in-stent
restenosis, unprotected left main, thrombus, or total occlusion.
Outcomes were adjudicated by an independent clinical
events committee comprised of cardiologists who were not
participants in the study. Clinical event adjudication deﬁ-
nitions were the same as those used in other studies
comprising the RESOLUTE Global Clinical Program.
Safety oversight was provided by a data safety monitoring
board composed of 2 cardiologists and a statistician not
participating in the study. Safety data were reviewed on a
regular basis, and the board could recommend early study
closure to the sponsor and steering committee. The Car-
diovascular Research Foundation (New York, New York)
coordinated the clinical events committee and data safety
monitoring board.
All analyses were conducted according to the intention-
to-treat principle, and no data imputation for missing values
was performed. Descriptive statistics and 95% conﬁdence
intervals were calculated for clinically relevant variables.
The sample size was calculated assuming a 1-year TLF
rate of 6.8%, which was derived from the E-Five registry.9
The E-Five registry used a similar all-comers registry design
to the RESOLUTE China Registry, used the ﬁrst-generation
ZES approved in China at the time of sample size calcula-
tion (Endeavor, Medtronic Inc, Santa Rosa, California), and
included sites in China.9 A sample size of 1,800 patients
would provide a 95% conﬁdence interval with a 1.2%
margin of error and would allow for a maximum of 5% rate
of loss to follow-up.
Table 2
Lesion, vessel, and procedural characteristics
Characteristic All Patients (n ¼ 1,800
Patients; n ¼ 2,320 Lesions)
Monitored (n ¼ 898
Patients; n ¼ 1,129 Lesions)
Unmonitored (n ¼ 902
Patients; n ¼ 1,191 Lesions)
p Value*
Vessel location (patients)
Left anterior descending 1,120 (62) 552 (62) 568 (63) 0.528
Left circumﬂex 416 (23) 195 (22) 221 (24) 0.163
Right 577 (32) 282 (31) 295 (33) 0.579
Left main 40 (2) 19 (2) 21 (2) 0.873
Saphenous vein graft 13 (1) 5 (1) 8 (1) 0.580
Left/right internal mammary artery 2 (<1) 2 (<1) 0 0.249
Chronic total occlusion (lesions) 167 (7) 89 (8) 78 (7) 0.228
Class B2/C (lesions) 1,570 (68) 756 (67) 814 (68) 0.478
Bifurcation (lesions) 345 (15) 164 (15) 181 (15) 0.683
Lesion length (mm) 24.91  13.73 24.93  14.54 24.89  12.93 0.945
Preprocedural reference vessel diameter (mm) 3.03  0.50 3.02  0.50 3.03  0.51 0.846
Preprocedural minimal lumen diameter (mm) 0.49  0.56 0.48  0.53 0.50  0.59 0.278
Preprocedural diameter stenosis (%) 84.06  17.77 84.42  17.00 83.71  18.46 0.334
Number of lesions treated per patient 1.4  0.7 1.4  0.7 1.4  0.7 0.836
Total stent length per patient (mm) 42.2  28.3 42.14  29.29 42.34  27.31 0.878
Total stent length per lesion (mm) 29.5  15.5 29.48  16.16 29.51  14.77 0.960
Number of stents per patient 1.8  1.1 1.79  1.07 1.79  1.03 0.997
Number of stents per lesion 1.3  0.5 1.26  0.55 1.26  0.52 0.784
Data are expressed as patients/lesions (%) or mean  SD. Lesion characteristics were visually estimated and site reported.
* Comparing monitored and unmonitored.
Table 3
Clinical and safety events through 1 year after R-ZES implantation
Clinical Event All Patients (n ¼ 1,750) Monitored (n ¼ 873) Unmonitored (n ¼ 877) Adjusted p Value*
TLF 61 (3.5) 34 (3.9) 27 (3.1) 0.264
Target vessel failure 68 (3.9) 37 (4.2) 31 (3.5) 0.331
MACE 70 (4.0) 40 (4.6) 30 (3.4) 0.142
Composite outcome 109 (6.2) 62 (7.1) 47 (5.4) 0.083
Cardiac death or target vessel myocardial infarction 52 (3.0) 30 (3.4) 22 (2.5) 0.197
Death or target vessel myocardial infarction 60 (3.4) 36 (4.1) 24 (2.7) 0.078
Death 20 (1.1) 10 (1.1) 10 (1.1) 0.900
Cardiac death 11 (0.6) 4 (0.5) 7 (0.8) 0.413
Noncardiac death 9 (0.5) 6 (0.7) 3 (0.3) 0.283
Target vessel myocardial infarction 41 (2.3) 26 (3.0) 15 (1.7) 0.062
Clinically driven target lesion revascularization 16 (0.9) 6 (0.7) 10 (1.1) 0.396
Clinically driven target vessel revascularization 25 (1.4) 10 (1.1) 15 (1.7) 0.412
Deﬁnite/probable stent thrombosis 8 (0.5) 1 (0.1) 7 (0.8) 0.089
Early (30 days) 7 (0.4) 1 (0.1) 6 (0.7) 0.126
Late (31e360 days) 1 (0.1) 0 1 (0.1) 0.902
Signiﬁcant bleeding 25 (1.4) 14 (1.6) 11 (1.3) 0.462
Data are expressed as patients (%). Refer to the Methods section for end point deﬁnitions.
* Comparing monitored and unmonitored.
Coronary Artery Disease/All-Comers Registry of R-ZES in China 615Baseline characteristics and outcomes through 1 year of
follow-up were compared between monitored and unmoni-
tored patients, and descriptive statistics were done for key
subgroups: men, women, bifurcation, diabetes, multivessel
treatment, chronic total occlusion, acute coronary syndromes,
long lesion (>27 mm), small vessel (<2.5 mm), ST-segment
elevation myocardial infarction, and noneST-segment
elevation myocardial infarction or unstable angina. To adjust
for differences in baseline patient characteristics between
groups, propensity scores were calculated using logistic
regression with treatment group as the dependent variable and
the covariates as the predictors. The baseline characteristicsincluded in the propensity score models were age, sex, dia-
betes, current smoker, hyperlipidemia, hypertension, previous
myocardial infarction, previous coronary artery bypass graft,
unstable angina or myocardial infarction, lesion in left
ascending artery, B2/C lesion, moderate-to-severe calciﬁca-
tion, tortuosity 45, Thrombolysis In Myocardial Infarction
ﬂow 3, reference vessel diameter, lesion length, and percent
diameter stenosis.
The effect of DAPT adherence on deﬁnite or probable
stent thrombosis events through 1 year of follow-up was
analyzed. Patients were grouped according to the time of
ﬁrst interruption of either aspirin or thienopyridine therapy
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Figure 1. Cumulative incidence through 1 year after R-ZES implantation of (A) TLF, (B) cardiac death or target vessel myocardial infarction, (C) MACE, and
(D) Academic Research Consortium deﬁnite or probable stent thrombosis (ST). Refer to the Methods section for outcome deﬁnitions.
616 The American Journal of Cardiology (www.ajconline.org)after procedure. Patients were included in this analysis if
they started on DAPT within 1 day after stent implantation,
had no previous stent thrombosis events observed during the
study, and had follow-up data available regarding the DAPT
use. The association between DAPT adherence and stent
thrombosis events was analyzed in 3 main groups: patients
with no interruption, interruption during the ﬁrst month after
procedure, and interruption during 1 to 12 months after
procedure.
Statistical analyses were performed using SAS software,
version 9.1 or later (SAS Institute, Cary, North Carolina).
p Values <0.5 were considered statistically signiﬁcant.Results
There were 1,800 patients with 2,320 lesions enrolled,
and follow-up at 1 year was 97% (n ¼ 1,750). Baseline
patient demographic and clinical characteristics are listed in
Table 1, and lesion characteristics are listed in Table 2. The
mean age of the patients was 61.3  10.9 years, 76% were
men, and 61% were complex. Most patients were treated in
de novo lesions (98%, n ¼ 2,281). Lesion success was
100% (2,319 of 2,320), device success was 97% (2,244 of
2,320), and procedure success was 98% (1,763 of 1,799).
Predilatation was used in 83% (1,919 of 2,320) and direct
stenting in 17% (401 of 2,320) of lesions. Overlapping
stents were used in 20% (n ¼ 368) of patients (507 lesions).
Glycoprotein IIb/IIIa inhibitors were used in 16% (n ¼ 317of 1,937) of procedures. DAPT use was 96% (n ¼ 1,712 of
1,780) at 6 months and 94% (n ¼ 1,633 of 1,730) at 1 year.
The primary outcome of 1-year TLF was 3.5% (n ¼ 61 of
1,750, 95% conﬁdence interval 2.7% to 4.5%; Table 3 and
Figure 1) and was primarily driven by target vessel
myocardial infarction. There were 8 total events of deﬁnite
or probable stent thrombosis: 7 early (30 days) and 1 late
(31 to 360 days; Table 3 and Figure 1). The rate of signif-
icant bleeding complications was 1.4% (n ¼ 25 of 1,750) at
1 year, and 5 of these 25 patients received glycoprotein IIb/
IIIa inhibitors at stent implantation.
There were 898 patients who were monitored (902 were
unmonitored). Baseline characteristics were similar between
monitored and unmonitored patients, except for insulin-
dependent diabetes and mean serum creatinine level. Clin-
ical outcomes at 1 year were also similar between monitored
and unmonitored patients (Table 3).
Subjects with MACE or stent thrombosis within the ﬁrst
month (n ¼ 44) were compared with those who had neither
event at that time (n ¼ 1,754). The population of ﬁrst-month
MACE or patients with stent thrombosis had a greater
proportion with diabetes (54% vs 29%, p <0.001), complex
disease (86% vs 61%, p <0.001), and lesions in the left
main artery (9% vs 2%, p ¼ 0.015). The ﬁrst-month MACE
or stent thrombosis population also had higher mean number
of lesions per patient (1.8  0.8 vs 1.4  0.7, p ¼ 0.004),
total stent length per patient (59.8  37.4 vs 41.8 
27.9 mm, p ¼ 0.003) and per lesion (35.19  20.56 vs 29.32
 15.25 mm, p ¼ 0.022), and total number of stents per
Table 4
Clinical outcomes for key subgroups at 1 year of follow-up
Subgroup (Total Patients) TLF Cardiac Death or
Target Vessel
Myocardial Infarction
Clinically Driven
Target Lesion
Revascularization
MACE Deﬁnite/Probable
Stent Thrombosis
Men (n ¼ 1,361) 44 (3.3) 39 (3.0) 12 (0.9) 52 (3.9) 7 (0.5)
Women (n ¼ 439) 17 (3.9) 13 (3.0) 4 (0.9) 18 (4.2) 1 (0.2)
1 Bifurcation lesion treated (n ¼ 315) 18 (6.0) 14 (4.7) 7 (2.3) 19 (6.3) 1 (0.3)
Diabetes (n ¼ 528) 33 (6.4) 29 (5.6) 8 (1.6) 35 (6.8) 4 (0.8)
Multivessel disease (n ¼ 505) 30 (6.1) 27 (5.5) 5 (1.0) 31 (6.3) 2 (0.4)
1 Chronic total occlusion lesion treated (n ¼ 157) 7 (4.7) 7 (4.7) 1 (0.7) 8 (5.3) 1 (0.7)
Acute coronary syndromes (n ¼ 1,190) 40 (3.4) 32 (2.7) 14 (1.2) 46 (3.9) 5 (0.4)
1 Long lesion treated, >27 mm (n ¼ 576) 35 (6.3) 32 (5.7) 8 (1.4) 39 (7.0) 6 (1.1)
1 Small vessel treated, reference vessel diameter
<2.5 mm (n ¼ 183)
8 (4.4) 6 (3.3) 4 (2.2) 10 (5.5) 3 (1.6)
Data are expressed as patients (%). Refer to the Methods section for end point deﬁnitions.
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Figure 2. Academic Research Consortium (ARC) deﬁnite or probable stent thrombosis (ST) rates through 1 year according to the DAPT status. The never
interrupted group included those who had no interruptions except for ST occurring while on DAPT. CI ¼ conﬁdence interval.
Coronary Artery Disease/All-Comers Registry of R-ZES in China 617patient (2.4  1.4 vs 1.8  1.0, p ¼ 0.004) and per lesion
(1.43  0.67 vs 1.25  0.53, p ¼ 0.031). All other baseline
patient and lesion characteristics were similar between these
groups (data not shown).
Clinically important subgroups were analyzed for key
1-year outcomes. The results of these analyses are presented
in Table 4.
There were 1,760 patients included in the DAPT analysis
(Figure 2); 1,576 patients had no interruption of their DAPT
during the year after R-ZES implantation. After R-ZES treat-
ment, 39patients had aDAPT interruption from implantation to
1month, 53 patients from1 to 6months, and 92 patients from6
to 12 months. There were 7 deﬁnite or probable stent throm-
bosis events in patients with no DAPT interruption and 1 stent
thrombosis event in a patient with DAPT interrupted within
1 month of treatment. No patient with an interruption from 1 to
6 or 6 to 12 months experienced a stent thrombosis (Figure 2).Discussion
We report 1-year results from a large, national, all-comers
registry of R-ZES use in Chinese patients. The previouslyreported RESOLUTE China Randomized Controlled Trial
(RCT)10 compared the R-ZES and the paclitaxel-eluting stent
in an all-comers Chinese population. The study found that
R-ZES had signiﬁcantly lower in-stent late luminal loss at
9 months. The clinical and safety end points at 9 months and
1 year after R-ZES implantation were also similar to those
observed in other studies comprising the RESOLUTE Global
Clinical Program. Results from the RESOLUTE China RCT
suggest that R-ZES is as safe and effective in Chinese pa-
tients as in previously studied populations. Patients in the
RESOLUTE China Registry experienced a low rate of TLF
and deﬁnite or probable stent thrombosis; these outcomes
were consistent with the results observed among R-ZES
patients in the RESOLUTE China RCT. Most events
occurred within the ﬁrst 30 days after the index procedure.
DAPT interruption was not associated with late stent
thrombosis. Clinical outcomes did not differ between moni-
tored and unmonitored patients.
Because of its all-comers design, the population in our
study included a mix of patients with complex and simple
diseases. As in other RESOLUTE studies with all-comers
designs,2,4,10 the protocol did not restrict enrollment for
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618 The American Journal of Cardiology (www.ajconline.org)either complex or simple (e.g., stable angina) disease states.
A high proportion (61%) had complex disease according to
prespeciﬁed criteria, a rate that is consistent with the other
RESOLUTE studies with all-comers designs: RESOLUTE
China RCT (55.1%), RESOLUTE All Comers (67.0%), and
RESOLUTE International (67.5%).2,4,10 The all-comers
design of this study increased the likelihood that we would
enroll a population that would be representative of real-
world PCI practice in China.
The rates of clinical events observed in our studywere lower
than those in other all-comers studies in the RESOLUTE
GlobalClinical Program:RESOLUTEChinaRCT (n¼ 198),10
RESOLUTE All Comers (n ¼ 1,140),2 and RESOLUTE
International4 (n ¼ 2,349; Figure 3). Outcome deﬁnitions and
adjudication practices were harmonized across studies in this
program, ensuring similar criteria for reportedoutcomesdespite
differences in population or study conduct. In all these studies,
most TLF occurred within the ﬁrst 30 days (Figure 3). Lesions
treated per patient did not vary greatly among these studies, but
mean total lesion length in RESOLUTE China Registry was
considerably lower. The apparent difference in lesion length
may have led to the comparably lower clinical event rates in the
RESOLUTE China Registry.
The clinical event rates observed in the RESOLUTE China
Registry were comparable with those of other all-comers
new-generation DES registries. The XIENCE V USA11 studyof real-world patients treated with the everolimus-eluting
stent (EES; XIENCE V, Abbott Laboratories, Santa Clara,
California) reported a 1-year TLF rate of 6.7%, similar to
RESOLUTE International. This study analyzed standard-risk
(on label) and extended-risk (higher risk characteristics)
patients; TLF was 3.5% compared with 8.5% in these groups,
respectively. The EXCELLENT (Efﬁcacy of Xience/promus
versus Cypher to rEduce Late Loss after stENTing) registry12
conducted in Korea analyzed outcomes in 3,056 patients after
treatment with EES. The 1-year rate of TLF was 2.7%. The
proportion of complex patients (reported as those with at least
1 off-label indication) was 73%. The outcomes of the
EXCELLENT registry were compared with the RESOLUTE-
Korea registry, which prospectively enrolled 1,998 patients
treated with the R-ZES without exclusions. The results of this
registry were similar with a 1-year TLF rate of 2.9% (p ¼
0.662 compared with EES), although the proportion of com-
plex patients was signiﬁcantly greater than in EXCELLENT
(81%, p<0.001). All clinical event rates were similar between
the 2 registries.12 The RESOLUTE China, EXCELLENT, and
RESOLUTE-Korea registries were similar in lesion charac-
teristics. The mean age, proportion of male patients, propor-
tion of patients with diabetes and hypertension, total stent
length per patient or lesion, and the number of stents per
patient or lesion appeared to be similar between the 3 studies.
Such similarities in baseline characteristics and follow-up
Coronary Artery Disease/All-Comers Registry of R-ZES in China 619outcomes indicate that the results of the RESOLUTE China
Registry are generalizable to Asian populations implanted
with new-generation DESs.
The RESOLUTE China Registry extends the growing
body of evidence that rates of stent thrombosis are low in
new-generation DESs through 1 year of real-world follow-up.
We observed a rate of deﬁnite or probable stent thrombosis of
0.5%. In the aforementioned RESOLUTE Global Clinical
Program all-comers studies,2,4,10 rates of deﬁnite or probable
stent thrombosis ranged from 0.5% to 1.3%. Deﬁnite or
probable stent thrombosis occurred in 0.8% of patients treated
with an EES in the XIENCE V USA registry11 through
1 year, which is similar to the rate of 0.6% reported for EES
in EXCELLENT.12 These rates of stent thrombosis appear to
be similar to the rate of 0.5% in our study and 0.4% reported
in the RESOLUTE-Korea registry.12 DAPT usage was 97%
at 6 months and 85% at 1 year in the Korea registries,12 79%
at 1 year in XIENCE V USA,11 and 94% at 1 year in the
RESOLUTE China Registry.
Our observation that most stent thrombosis events occur
early (<30 days) is consistent across all DES studies, but the
effect of DAPT adherence is not well understood—especially
in new-generation DESs. We found that there were no stent
thrombosis events in patients with a DAPT interruption after
1 month. This is consistent with results from an analysis of a
larger R-ZES data set from the RESOLUTE Clinical Global
Program recently reported at the American College of
Cardiology.13 There were 32 (0.8%) of 3,827 stent throm-
bosis events in patients with no DAPT interruption, 6 (3.6%)
of 166 stent thrombosis events in patients with DAPT inter-
rupted 0 to 1 month after R-ZES treatment, and 1 (0.1%) of
903 in patients with DAPT interrupted between 1 and
12 months. A prolonged use of antiplatelet drugs is a known
risk for bleeding events, and there is evidence to suggest that
for some patients, DAPT extension beyond 3 months confers
no additional beneﬁt in terms of reduction in stent thrombosis
events but is associated with more major bleeding events.14
There was no control group in the RESOLUTE China
Registry, and clinical monitoring was less than that used in
randomized controlled clinical trials. However, outcomes
did not differ signiﬁcantly between monitored and unmon-
itored patients, and the monitoring rate of 50% was higher
than that in other large registries. Another limitation is that
the study reﬂected common clinical practice by relying on
site-reported visual assessments of angiographic data.
The RESOLUTE China Registry is a prospective, multi-
center, all-comers registry that provides valuable insight into
patient characteristics, usage patterns, and clinical outcomes in
routine interventional cardiology practice. The RESOLUTE
China Registry demonstrated a low rate of cardiac events,
including low deﬁnite or probable stent thrombosis. The results
observed in this registry conﬁrm the results seen in the
RESOLUTEChina RCT and are consistent with those in other
registries conducted in Asian populations. This large real-
world study further supports the favorable performance of the
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